On-X LTI prepares European sales force to sell On-X® Plus 1.5™ Aortic Heart Valve “While the On-X® Plus 1.5™ Aortic Heart Valve represents a new paradigm by which clinicians can manage their patients on a reduced dose of warfarin, we are proud to note that On-X has been successfully selling mechanical valves in Europe since […]
On-X LTI Launches Innovative Heart Valve Products
European Meeting in Barcelona The On-X aortic valve with an anatomic shaped sewing ring and ePTFE suture for repair of mitral valve chordae presented at EACTS AUSTIN, TX – October 29, 2012 – On-X® Life Technologies, Inc. (On-X LTI) announced today that it is launching two new heart valve products, the On-X® Aortic Prosthetic Valve […]
On-X Life Technologies to Highlight
Reduced Anticoagulation Study Results, Long-Term and Patient Survival Data with the On-X heart valve at STS Meeting Interim results for PROACT Trial, two ten-year clinical research reports and several clinical reports indicating longer survival for mechanical valve patients available to surgeons at The Society of Thoracic Surgeons Meeting AUSTIN, TX – January 24, 2012 – […]
On-X Heart Valve’s Exceptional Clinical Performance
Important Clinical Research Featuring the On-X Heart Valve to be Presented at The Biennial Meeting of the Society for Heart Valve Disease in Barcelona, Spain AUSTIN, Texas, Jun 27, 2011 (BUSINESS WIRE) — On-X(R) Life Technologies, Inc. (On-X LTI) announced today that four clinical trial reports, documenting the On-X(R) Prosthetic Heart Valve’s extraordinary performance, will be presented at the upcoming meeting of the Society for Heart Valve Disease in Barcelona, Spain being held June 25-28, 2011. The reports will include interim clinical results from the Prospective Randomized On-X Anticoagulation Clinical Trial (PROACT), which is being conducted in 36 major institutions in the United States, a comparison of the On-X heart valve with three competitive mechanical valves in Australia, a Ten-year Multiple Center European Study and a Ten-year Study in Poorly Controlled Anticoagulated Patients in South Africa
On-X LTI to Host Satellite Symposium
On-X LTI to Host Satellite Symposium at Society of Thoracic Surgeons (STS) Meeting New Considerations for Prosthetic Valve Choice” challenges current prosthetic heart valve trends AUSTIN, TX — January 25, 2011 — On-X® Life Technologies, Inc. (On-X LTI) announced today that it will host a Satellite Symposium during the Society of Thoracic Surgeons meeting in […]
On-X LTI Receives FDA Approval for AAP
On-X LTI Receives FDA Approval for Aortic Valve with Vascutek Graft Innovative On-X aortic valve is now available with market-leading pre-attached Gelweave Valsalva™ Vascular Prosthesis AUSTIN, TX — January 21, 2011 — On-X® Life Technologies, Inc. (On-X LTI) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market […]
